JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Mikaktilar Yozshutaxe
Country: Czech Republic
Language: English (Spanish)
Genre: Software
Published (Last): 21 April 2008
Pages: 180
PDF File Size: 2.27 Mb
ePub File Size: 4.74 Mb
ISBN: 511-3-17589-940-4
Downloads: 31523
Price: Free* [*Free Regsitration Required]
Uploader: Tetaur

The drive towards more stringent goals for LDL-C lowering in cardiovascular risk prevention has brought high impact statin therapy into focus.

The participants had a mean Framingham risk score at baseline of Special groups Patients rosuvsatatina hereditary hyperlipidaemia, particularly FH and FCH should be considered for early treatment with rosuvastatin. Open in a separate window.

Furthermore these patients are at extremely high cardiovascular risk. Implications of the Justification for Use of Statins in Prevention: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hyperc holesterolemia—Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin PULSAR.

The mean volume of distribution is litres in steady state. This has implications on their muscle safety as increased rhabdomyolysis was reported in patients on lipophilic agents like cerivastatin and lovastatin.

The SPARCL study showed that intensive statin therapy with atorvastatin 80 mg daily resulted in significant reduction in recurrent stroke. Clearfield MB, Amerena J, et al. The use of rosuvastatin did however reduce hospitalisation from cardiovascular causes. Its potential impact in primary and secondary prevention of cardiovascular disease in different groups including heart failure, elderly, renal failure and diabetes, and also in combination with other lipid lowering drugs is the subject of ongoing clinical studies.


A raNdomized, Double-blind, double-dummy, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of Rosuvastatin 10 mg and 20 mg and atOrvastatin 10 mg and 20 mg in patiEnts with type 2 DiAbetes mellitus. ApoA-1 ratio as an important predictor of myocardial infarction.

Rosuvastatin belongs to a new generation of methane- sulphonamide pyrimidine and N -methane sulfonyl pyrrole-substituted 3, 5- dihydroxy-heptenoates. Table 4 shows the hazard ratios of developing myopathy or liver dysfunction with different statins. Drugs that increase plasma concentrations of rosuvastatin.

This, coupled with its minimal CYP metabolism confers relatively better tolerability, safety and drug interaction profile. Randomised trial of cholesterol rosuvaatatina in patients with coronary heart disease: This in turn reduces endothelial dysfunction that has been implicated in atherosclerosis.

Several studies have suggested that reduction in plaque volume is linked to the clinical outcome. However, the reduction in total and cardiovascular mortality was not significant due to the small sample size.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Because of ju;iter potency, rosuvastatin can be used at very low doses. We conducted a Medline literature search to identify rosuvastatin papers published in English.

Finally we will address its place in clinical practice. A further evaluation of secondary outcomes showed no reduction in all-cause mortality or non-cardiovascular death. These results indicate the potential value of genetic profiling of patients to optimise statin response in a cost effective manner. This enzyme converts HMG-CoA to mevalonic acid in the cholesterol biosynthetic pathway which is the rate limiting step in cholesterol synthesis. Combination therapy Jupiger high risk patients or those with severe dyslipidaemia often require combination therapy to achieve treatment goals and enhance lipid profile modification.

We will also review clinical studies with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Effects eosuvastatina lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Finally we address its place in clinical practice. These benefits were present in all patient groups including women, non smokers and other low risk patients.



Furthermore the combination of rosuvastatin with fenofibric acid was well tolerated and as safe as each drug used as monotherapy. The use of LDL apheresis in heterozygous FH esudio is thus unclear and at present maximal drug therapy is the preferred treatment.

Place in Therapy Rosuvastatin is a potent statin with pharmacologic and pharmacokinetic advantages. It has low extrahepatic tissue roxuvastatina, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. Another series of sub analyses have looked at lipid profiles and hsCRP particularly in relation to residual cardiovascular risk.

Use of Rosuvastatin versus Atorvastatin in type 2 diabetes mellitus. In this review, we will outline the pharmacology of rosuvastatin; highlight its efficacy and safety.

Scandinavian Simvastatin Survival Study Group. A randomised controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: Economic evaluations show that intensive lipid lowering is a cost effective treatment for very high risk patients groups including those with ACS, heterozygous FH and diabetes. It therefore appears that the risk of developing diabetes is marginally higher with rosuvastatin compared to other statins.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

The absolute risk of developing diabetes was 0. ASH has received fees consulting for AstraZeneca. Measuring Effects on Intima Media Thickness: Its affinity for OATP-1B1 is comparable to atorvastatin but significantly greater than pravastatin or simvastatin.